A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells function to prevent the immune system from over-reacting B12 to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients with hay fever by vitamin providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears B12 that by helping the immune system to become vitamin what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic B12 or moderately-allergic people.

Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic vitamin rhinitis (hay fever), B12 sinusitis, asthma,...conjunctivitis, vitamin urticaria, eczema, dermatitis (contact and atopic)...allergic B12 and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary vitamin lung functions were taken at days 45, B12 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites vitamin in B12 Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from Day 0 to Day 30.3

In 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned vitamin a second set B12 of symptom diaries which they had completed for days 365 to 395 (the same period, vitamin one year after the first set of symptom B12 diaries). The active group had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo vitamin group had increased symptoms in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7

©2003 www.asian-homeopathic-remedies.com All rights reserved.